含黄芪中药联合西药治疗狼疮肾炎的系统评价与Meta分析
本研究系统检索多个数据库,纳入14项随机对照试验共800例狼疮肾炎患者,评价含黄芪中药联合西药对比单用西药的疗效与安全性。Meta分析显示联合治疗可改善SLEDAI评分、24小时蛋白尿、血肌酐、血尿素氮及总有效率,并降低不良事件发生率。
要点
- 含黄芪中药联合西药可改善狼疮肾炎患者SLEDAI评分及肾功能指标。
- 联合治疗组总有效率高于单用西药组,不良事件发生率更低。
- 试验序贯分析提示总有效率和不良事件的数据结论稳健。
核心结论
- 含黄芪中药联合西药治疗狼疮肾炎可能提高疗效并降低毒性。
研究设计与样本
- 系统评价与Meta分析,纳入14项随机对照试验,共800例患者(治疗组417例,对照组383例)。
- 检索PubMed、Web of Science、Embase、CNKI和万方数据库,采用固定或随机效应模型合并数据。
主要发现
- SLEDAI评分改善:SMD=1.01,95%CI 0.71-1.30,P<0.001。
- 24小时蛋白尿改善:SMD=0.51,95%CI 0.35-0.66,P<0.001。
- 血肌酐改善:SMD=0.64,95%CI 0.27-1.01,P<0.001;血尿素氮改善:SMD=0.73,95%CI 0.53-0.92,P<0.001。
- 总有效率提高:RR=1.21,95%CI 1.10-1.34,P<0.001;不良事件发生率降低:RR=0.56,95%CI 0.42-0.73,P<0.001。
关键数值与推荐
- 总有效率RR=1.21(95%CI 1.10-1.34,P<0.001),不良事件RR=0.56(95%CI 0.42-0.73,P<0.001)。
- 试验序贯分析提示总有效率和不良事件发生率的数值结论可靠。
临床怎么用
- 在狼疮肾炎标准西药治疗基础上,可考虑联合含黄芪中药以改善疾病活动度和肾功能。
- 联合治疗可能降低腹泻、发热等不良事件发生率,但需结合患者个体情况辨证使用。
局限性
- 原文未报告纳入试验的具体偏倚风险评价细节。
- 原文未报告随访时长、复发率及长期肾脏结局等数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) that requires effective management to prevent kidney damage and other systemic effects. While Western medicine provides the standard treatment, incorporating traditional Chinese medicine, such as Astragalus-containing Chinese herbal medicine (CHM), may offer additional benefits in improving patient outcomes. OBJECTIVE: This study aims to conduct a systematic review and meta-analysis of the efficacy and safety of Astragalus in conjunction with Western medicine for the treatment of LN. METHODS: We conducted a comprehensive, global systematic search across databases including PubMed, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang. Data were synthesized using fixed- or random-effects models, depending on the level of heterogeneity. Results were presented as standardized mean difference (SMD), risk ratios (RRs), or number needed to treat (NNT) with 95% confidence intervals (CIs). The Cochrane Q test and I2 statistics were used to test the heterogeneity assessment. Trial sequential analysis (TSA) was employed to assess the power of the results. All statistical analysis was carried out using STATA (version 16.0). RESULT: The analysis included 14 RCTs, with a total of 800 patients (417 in the treatment group and 383 in the control group). Our meta-analysis revealed that patients treated with Astragalus-containing CHM alongside Western medicine showed markedly improved outcomes compared to those receiving only Western medicine. Significant improvements were observed in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores (SMD = 1.01, 95% CI: 0.71-1.30, P < 0.001), 24-h proteinuria (SMD = 0.51, 95% CI: 0.35-0.66, P < 0.001SMD = 0.51, 95% CI: 0.35-0.66, P < 0.001), serum creatinine (SCr) levels (SMD = 0.64, 95%CI: 0.27-1.01, P < 0.001), blood urea nitrogen (BUN) levels (SMD = 0.73, 95%CI: 0.53-0.92, P < 0.001), and overall response rates (ORR) (RR = 1.21, 95%CI: 1.10-1.34, P < 0.001). Additionally, the incidence of adverse events (AEs), such as diarrhea, fever, and other symptoms, was significantly lower in the group treated with Astragalus-containing CHM and Western medicine (RR = 0.56, 95%CI: 0.42-0.73, P < 0.001). The TSA indicated that the data were sufficiently robust to draw reliable numerical conclusions regarding the ORR and the incidence of AEs. CONCLUSION: The inclusion of Astragalus-containing CHM alongside Western medicine may be a promising strategy for to improve the therapeutic effectiveness and reduce toxicity in the treatment of LN.
引用
- Li J, Wu M, Liu W, et al. Astragalus-containing Chinese herbal medicine used with Western medicine for lupus nephritis: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025. PMID: 40061256. doi:10.3389/fphar.2024.1395844
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。